Q32 Bio Inc. QTTB
Set alert
8.91 USD +0.04 +0.45%
At close · Oct 30
8.88 -0.03 -0.34%
After hours · Oct 30, 4:30 PM ET
8.53 Day range 8.98
1.93 52-week range 21.38
- YTD
- +168.37%
- 1 year
- +222.83%
- Open
- 8.87
- Prev close
- 8.87
- Mkt cap
- 265.25M
- Vol
- 268.18K
- Avg vol
- 713.73K
- EPS
- 3.15
- P/E
- 2.83
- Div yield
- 0.00%
More statistics
- Low
- 8.53
- High
- 8.98
- Forward P/E
- -0.60
- Beta
- 0.00
- Short ratio
- 6.74
- Inst. own
- 86.21%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 32.96
- 200-d avg
- 30.53
- 1y target
- 17.40
2Y chart
Events in this range
- Nov 7, 2024Earnings: -1.46; estimate -1.41; surprise -3.55%
- Dec 11, 2024Downgrade: Leerink Partners · Outperform → Market Perform
- Dec 11, 2024Downgrade: Wells Fargo · Overweight → Equal-Weight
- Dec 11, 2024Rating: Piper Sandler · Overweight → Overweight
- Dec 11, 2024Rating: Oppenheimer · Outperform → Outperform
- Dec 12, 2024Downgrade: Guggenheim · Buy → Neutral
- Dec 12, 2024Rating: BMO Capital · Outperform → Outperform
Signals (68)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 15, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 8, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 30, 2026 | 1 month ago |
| RSI: Oversold | Sep 30, 2026 | 1 month ago |
| RSI: Oversold | Sep 16, 2026 | 1 month ago |
| RSI: Oversold | Sep 4, 2026 | 1 month ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 20, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 13, 2026 | 3 months ago |
| RSI: Overbought | Jul 13, 2026 | 3 months ago |
| MACD: Sell Signal | Jun 16, 2026 | 4 months ago |
| RSI: Overbought | Jun 4, 2026 | 4 months ago |
| RSI: Overbought | Jun 2, 2026 | 5 months ago |
| RSI: Overbought | May 27, 2026 | 5 months ago |
| SMA: Bullish | May 26, 2026 | 5 months ago |
| SMA: Bearish | May 20, 2026 | 5 months ago |
| SMA: Bullish | May 19, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| MACD: Buy Signal | May 13, 2026 | 5 months ago |
| SMA: Bearish | Apr 27, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 27, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 21, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Apr 9, 2026 | 6 months ago |
| MACD: Sell Signal | Mar 30, 2026 | 7 months ago |
| RSI: Overbought | Mar 24, 2026 | 7 months ago |
| RSI: Overbought | Mar 10, 2026 | 7 months ago |
| MACD: Buy Signal | Feb 20, 2026 | 8 months ago |
| SMA: Bullish | Feb 12, 2026 | 8 months ago |
| SMA: Bearish | Feb 11, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 4, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 3, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 30, 2026 | 9 months ago |
| RSI: Overbought | Jan 21, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 2, 2026 | 10 months ago |
| MACD: Sell Signal | Dec 16, 2025 | 10 months ago |
| SMA: Bullish | Dec 1, 2025 | 11 months ago |
| MACD: Buy Signal | Dec 1, 2025 | 11 months ago |
| RSI: Overbought | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Nov 26, 2025 | 11 months ago |
| SMA: Bearish | Nov 20, 2025 | 11 months ago |
| SMA: Bullish | Nov 10, 2025 | 11 months ago |
| SMA: Bearish | Nov 6, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 22, 2025 | 1 year ago |
| RSI: Overbought | Oct 7, 2025 | 1 year ago |
| SMA: Bullish | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Sep 29, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 10, 2025 | 1 year ago |
| SMA: Bearish | Aug 26, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 26, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 25, 2025 | 1 year ago |
| SMA: Bullish | Aug 22, 2025 | 1 year ago |
| SMA: Bearish | Aug 19, 2025 | 1 year ago |
| SMA: Bearish | Aug 7, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jul 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 10, 2025 | 1 year ago |
| RSI: Overbought | Jul 10, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 11, 2025 | 1 year ago |
| SMA: Bearish | Jun 10, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| SMA: Bearish | May 30, 2025 | 1 year ago |
| SMA: Bullish | May 28, 2025 | 1 year ago |
| MACD: Buy Signal | May 12, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 30, 2025 | 1 year ago |
| RSI: Oversold | Apr 7, 2025 | 1 year ago |
| RSI: Oversold | Mar 28, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 24, 2024 | 1 year ago |
Key statistics
- Market cap
- 39.34M
- Enterprise value
- -23.25M
- Trailing P/E
- 0.00
- Forward P/E
- -0.60
- PEG ratio
- 0.00
- Price / sales
- -2.68
- Price / book
- 2.14
- EPS (TTM)
- -4.51
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- -14.66M
- Revenue growth
- 0.00%
- Free cash flow
- -71.27M
- Total cash
- 89.08M
- Total debt
- 22.10M
- Return on equity
- 0.00%
- Shares outstanding
- 12.18M
- Short % of float
- 0.00%
- 50-day average
- 32.96
- 200-day average
- 30.53
Analyst view
Consensus: buy
Buy
Price target (mean) 17.40 +95.3% upside
Now 8.91
- Target (low)
- 9.00
- Target (mean)
- 17.40
- Target (high)
- 22.00
Ratings (0m) 5 3 buy · 2 hold · 0 sell
- Strong buy2
- Buy1
- Hold2
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate 0.00.
Financials — quick view
QTTB Revenue — quarterly 0
QTTB Net income — quarterly -8.95M
QTTB EPS — quarterly -0.44
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -1.41 | -1.46 | -0.05 | -3.55% |
| Aug 8, 2024 | Jun 1, 2024 | -1.00 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -1.00 | -1.42 | -0.42 | -42.00% |
| May 9, 2024 | Mar 1, 2024 | -1.42 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -1.42 | -13.15 | -11.73 | -826.06% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 12, 2024 | BMO Capital | main | Outperform | Outperform |
| Dec 12, 2024 | Guggenheim | down | Buy | Neutral |
| Dec 11, 2024 | Oppenheimer | main | Outperform | Outperform |
| Dec 11, 2024 | Piper Sandler | main | Overweight | Overweight |
| Dec 11, 2024 | Wells Fargo | down | Overweight | Equal-Weight |
| Dec 11, 2024 | Leerink Partners | down | Outperform | Market Perform |
About Q32 Bio Inc.
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- q32bio.com
News
Your note
Sign in to keep a note on QTTB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLOWAY PAUL | President | Conversion of Exercise of derivative security | Mar 24, 2024 | 51,566 |
| BLUM MICHAEL LEE | Officer | Sale | Jan 8, 2023 | 9,408 |
| JORDAN JULIE | Officer | Conversion of Exercise of derivative security | Aug 2, 2023 | 7,496 |
| MICHAUD CHARLES JR. | Officer and Treasurer | Conversion of Exercise of derivative security | Mar 24, 2024 | 18,046 |
| SEYMOUR ALBERT B | Chief Executive Officer | Conversion of Exercise of derivative security | Sep 5, 2023 | 150,874 |
| SMITH W BRADFORD | Chief Financial Officer | Sale | Jan 8, 2023 | 14,219 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 18.50% | 2,252,987 | 7.28M | Sep 29, 2024 |
| Atlas Venture Life Science Advisors, LLC | 17.18% | 2,092,106 | 6.76M | Sep 29, 2024 |
| Carlyle Group Inc. | 9.05% | 1,102,741 | 3.56M | Sep 29, 2024 |
| FMR, LLC | 3.50% | 426,302 | 1.38M | Sep 29, 2024 |
| Blackrock Inc. | 3.35% | 408,659 | 1.32M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 3.32% | 404,411 | 1.31M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios - Biotechnology | 2.13% | 259,900 | 839.48K | Oct 30, 2024 |
| Fidelity Advisor Biotechnology Fund | 1.66% | 201,678 | 651.42K | Oct 30, 2024 |
| Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund | 1.56% | 190,000 | 613.70K | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 1.34% | 162,796 | 525.83K | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.28% | 155,361 | 501.82K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.63% | 76,718 | 247.80K | Sep 29, 2024 |